首页> Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research> CERTOLIZUMAB PEGOL IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA STUDY

CERTOLIZUMAB PEGOL IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA STUDY

导出原文传递

翻译打印收藏纠错

作者： Gladman, D. ^[1] ; Fleischmann, R. ^[2] ; Harris, K. ^[3] ; Peterson, L. ^[4] ; Mease, P. J. ^[5]

作者单位： Univ Toronto, Toronto, ON, Canada ^[1] UCB Pharma, Brussels, Belgium ^[2] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA ^[3] Swedish Med Ctr, Seattle, WA USA ^[4] UCB Pharma, Raleigh, NC USA ^[5]

发布时间 2020-08-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Value in health

2016年19卷7期

A594-A594页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

CERTOLIZUMAB PEGOL IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA STUDY

Value in health

相似文献

Value in health

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

CERTOLIZUMAB PEGOL IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA STUDY

Value in health

相似文献

Value in health

相关期刊

检索历史清除